Tofacitinib as an alternative therapy for refractory intestinal Behçet’s syndrome

BACKGROUND: Intestinal Behçet’s syndrome is a major cause of morbidity and mortality in Behçet’s syndrome. OBJECTIVES: Current treatment challenges remain in refractory intestinal Behçet’s syndrome, when patients failed first and second-line therapies. DESIGN: We reported the efficacy and safety pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Jun, Cai, Jian-fei, Ye, Jing-fen, Guan, Jian-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511299/
https://www.ncbi.nlm.nih.gov/pubmed/36171803
http://dx.doi.org/10.1177/1759720X221124014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511299/
https://www.ncbi.nlm.nih.gov/pubmed/36171803
http://dx.doi.org/10.1177/1759720X221124014

Ejemplares similares